CRCP

Across TCGA pan-cancer cohorts, CRCP mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRCP data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CRCP mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CRCP expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

GBM, HNSC, and LUAD are the cancer types where CRCP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.258	0.797	.035	14	view →
HNSC	DFS	Median	IV	0.915	0.473	.013	12	view →
LUAD	DFS	Quartile	All	0.415	1.000	.005	6	view →
LSCC	OS	Quartile	III,IV	0.408	0.986	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRCP–GBM (OS)

Open the GBM breakdown →